A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.
Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on Bayer Pharma's investment in High-Tech Gründerfonds II, a German venture fund that provides seed financing to local startups. Founders always have to give up something to access cash, but those who turned to Russia's venture capital sector for financing may have lost more than they realize. The U.S. claims Russian VC shops could be stealing tech. And more. Read the full report >>
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.
Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions in Europe.
Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.
Corey Goodman, the managing partner at venBio, is joining a group of VCs backing Ireland's Heart Metabolics, which is positioning a Phase III-ready heart disease drug for the clinic.
After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.
A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.
From Our Sister Sites
Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.
Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests.